Two Different Opioid Peptides Work Together to Lower Blood Pressure via Alpha-Methyldopa
Both beta-endorphin and dynorphin — but not enkephalin — are required for alpha-methyldopa's blood-pressure-lowering mechanism, and they must act early in the process.
Quick Facts
What This Study Found
Both beta-endorphin(1-31) and dynorphin(1-13), but not met-enkephalin, mediate alpha-methyldopa's central hypotensive effect. The opioid peptides must be released early in the drug's mechanism.
Key Numbers
How They Did This
Conscious normotensive rats received intracisternal antisera against specific opioid peptides, followed by intracisternal alpha-methyldopa. Blood pressure and heart rate were measured.
Why This Research Matters
This refined the understanding of how blood pressure drugs use the brain's opioid system. Two different opioid peptide families cooperate to produce the drug's effect.
The Bigger Picture
This study refined our understanding of how the brain's opioid system participates in blood pressure regulation. The cooperation between two different opioid peptide families (endorphins and dynorphins) suggests a more complex signaling network than previously appreciated.
What This Study Doesn't Tell Us
Animal study with intracisternal injection, not reflecting normal drug delivery. Only one blood pressure drug was tested. Results may not translate directly to humans.
Questions This Raises
- ?Do beta-endorphin and dynorphin act on the same or different neural circuits to lower blood pressure?
- ?Could combined opioid peptide therapy provide better blood pressure control?
Trust & Context
- Key Stat:
- Two opioid families cooperate Both beta-endorphin(1-31) and dynorphin(1-13) must act early in alpha-methyldopa's mechanism to lower blood pressure
- Evidence Grade:
- Preliminary animal study with direct brain injections. Provides mechanistic detail but uses non-physiological drug delivery routes.
- Study Age:
- Published in 1989. Companion paper to RPEP-00102, together building the case for opioid peptide involvement in antihypertensive drug mechanisms.
- Original Title:
- Possible involvement of beta endorphin(1-31) and dynorphin(1-13) in the central hypotensive mechanism of action of alpha methyldopa.
- Published In:
- Neuroendocrinology, 49(1), 71-9 (1989)
- Authors:
- van Giersbergen, P L(5), Wiegant, V M(3), de Jong, W(5)
- Database ID:
- RPEP-00141
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why are two different opioid peptides needed?
Beta-endorphin and dynorphin activate different opioid receptor types (mu and kappa respectively). Both pathways appear necessary for the full blood-pressure-lowering effect, suggesting they contribute through complementary neural circuits.
Why did blocking 3 hours later not work?
The opioid peptides appear to be involved in initiating the blood pressure response, not maintaining it. Once the cascade is triggered, the downstream effects continue independently of the initial opioid signal.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00141APA
van Giersbergen, P L; Wiegant, V M; de Jong, W. (1989). Possible involvement of beta endorphin(1-31) and dynorphin(1-13) in the central hypotensive mechanism of action of alpha methyldopa.. Neuroendocrinology, 49(1), 71-9.
MLA
van Giersbergen, P L, et al. "Possible involvement of beta endorphin(1-31) and dynorphin(1-13) in the central hypotensive mechanism of action of alpha methyldopa.." Neuroendocrinology, 1989.
RethinkPeptides
RethinkPeptides Research Database. "Possible involvement of beta endorphin(1-31) and dynorphin(1..." RPEP-00141. Retrieved from https://rethinkpeptides.com/research/van-1989-possible-involvement-of-beta
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.